PE75299A1 - Formulacion inyectable transparente de compuesto anestesico - Google Patents

Formulacion inyectable transparente de compuesto anestesico

Info

Publication number
PE75299A1
PE75299A1 PE1998000393A PE00039398A PE75299A1 PE 75299 A1 PE75299 A1 PE 75299A1 PE 1998000393 A PE1998000393 A PE 1998000393A PE 00039398 A PE00039398 A PE 00039398A PE 75299 A1 PE75299 A1 PE 75299A1
Authority
PE
Peru
Prior art keywords
solution
lecithin
injectable formulation
propofol
preference
Prior art date
Application number
PE1998000393A
Other languages
English (en)
Spanish (es)
Inventor
Tommaso Vincenzo De
Original Assignee
Saucy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saucy Ltd filed Critical Saucy Ltd
Publication of PE75299A1 publication Critical patent/PE75299A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE1998000393A 1997-05-26 1998-05-19 Formulacion inyectable transparente de compuesto anestesico PE75299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH01224/97A CH692322A5 (it) 1997-05-26 1997-05-26 Formulazione iniettabile limpida di Propofol.

Publications (1)

Publication Number Publication Date
PE75299A1 true PE75299A1 (es) 1999-08-26

Family

ID=4205400

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000393A PE75299A1 (es) 1997-05-26 1998-05-19 Formulacion inyectable transparente de compuesto anestesico

Country Status (23)

Country Link
US (1) US6326406B1 (ref)
EP (1) EP0991405B1 (ref)
JP (1) JP2001527577A (ref)
KR (1) KR20010013011A (ref)
CN (1) CN1268051A (ref)
AR (1) AR012853A1 (ref)
AT (1) ATE230984T1 (ref)
AU (1) AU735020B2 (ref)
BR (1) BR9809492A (ref)
CA (1) CA2291261A1 (ref)
CH (1) CH692322A5 (ref)
DE (1) DE69810771D1 (ref)
DZ (1) DZ2503A1 (ref)
HU (1) HUP0002117A3 (ref)
IN (1) IN187550B (ref)
MY (1) MY132911A (ref)
NO (1) NO995831L (ref)
PA (1) PA8451701A1 (ref)
PE (1) PE75299A1 (ref)
PL (1) PL337026A1 (ref)
TR (1) TR200000116T2 (ref)
WO (1) WO1998053805A1 (ref)
ZA (1) ZA984314B (ref)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
JP4198318B2 (ja) 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
CN1151782C (zh) * 1999-01-28 2004-06-02 迪内希·尚蒂拉尔·帕特尔 一种具有哺乳动物麻醉的诱导和保持以及镇静用途的药用注射液
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6635456B2 (en) * 2001-02-09 2003-10-21 Fidia Farmaceutici S.P.A. Procedure for the preparation of pure phosphatides with phospholipase D
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
KR100482269B1 (ko) * 2002-10-08 2005-04-14 센츄론(주) 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
JP2005154305A (ja) * 2003-11-21 2005-06-16 Showa Yakuhin Kako Kk ヒアルロン酸含有組成物の製造方法
CN100358513C (zh) * 2005-04-07 2008-01-02 常州市第四制药厂有限公司 一种丙泊酚注射液的制备工艺
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
NZ590802A (en) * 2008-11-20 2013-05-31 Techno Guard Co Ltd Formulation comprising a pyrazolone derivative and an amphiphilic solubilising agent
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
WO2019173526A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
JP7063217B2 (ja) * 2018-09-27 2022-05-09 住友電気工業株式会社 光ファイバの製造方法
JP7135670B2 (ja) * 2018-09-27 2022-09-13 住友電気工業株式会社 光ファイバ及び紫外線硬化型樹脂組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1089510B (de) * 1959-03-23 1960-09-22 Rudolf Reiss Dr Verfahren zur Herstellung waessriger, injizierbarer Loesungen von 2-Methoxy-4-allylphenoxyessigsaeure-N, N-Diaethylamid
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
DE3221579A1 (de) * 1982-06-08 1983-12-22 Eckert, Theodor, Prof. Dr., 4400 Münster Solubilisierung von in wasser schwerloeslichen wirkstoffen in waessrige loesung unter verwendung eines gemisches von cholinphosphorsaeureglycerindiester (cholin-lecithin) und natriumdesoxycholat als loesungsvermittler und die therapeutische verwendung der so erhaltenen waessrigen loesungen
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
DE4039602A1 (de) * 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
AU6708096A (en) * 1995-09-18 1997-04-09 Vesifact Ag Propofol nanodispersions
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations

Also Published As

Publication number Publication date
JP2001527577A (ja) 2001-12-25
NO995831L (no) 2000-01-26
HUP0002117A2 (hu) 2000-12-28
DZ2503A1 (fr) 2005-01-25
MY132911A (en) 2007-10-31
PL337026A1 (en) 2000-07-31
WO1998053805A1 (en) 1998-12-03
EP0991405B1 (en) 2003-01-15
AU8209798A (en) 1998-12-30
DE69810771D1 (de) 2003-02-20
ZA984314B (en) 1998-12-08
ATE230984T1 (de) 2003-02-15
AU735020B2 (en) 2001-06-28
US6326406B1 (en) 2001-12-04
CH692322A5 (it) 2002-05-15
EP0991405A1 (en) 2000-04-12
NO995831D0 (no) 1999-11-26
AR012853A1 (es) 2000-11-22
TR200000116T2 (tr) 2000-05-22
PA8451701A1 (es) 2000-05-24
CN1268051A (zh) 2000-09-27
CA2291261A1 (en) 1998-12-03
IN187550B (ref) 2002-05-18
BR9809492A (pt) 2000-06-20
KR20010013011A (ko) 2001-02-26
HUP0002117A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
CO5011119A1 (es) Jarabe antihistaminico estabilizado
NO964813D0 (no) Fremgangsmåte for stabilisering av duocarmycinderivater
PE1299A1 (es) Procedimiento para la preparacion de sildenafil
CY1108070T1 (el) Παραγωγα κινολινονης, ως αναστολεις κινασης τυροσινης
NO973059D0 (no) Hydroxylaminderivater som er anvendbare for å höyne den molekylære chaperonproduksjon, og fremstilling derav
ES2142798T3 (es) Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE485815T1 (de) Zubereitungen zur perkutanen absorption
NO338966B1 (no) Nye porfyrinderivater, fortrinnsvis kloriner og/eller bakteriokloriner, fremgangsmåte for fremstilling derav, og anvendelse derav som antikreft, og/eller antiviralt og/eller antimikrobielt medikament i fotodynamisk terapi
ES2071666T3 (es) Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
NO172674B (no) Fremgangsmaate for fremstilling av basiske, vandige preparater av karboksylsyrer
ES2178205T3 (es) Compuestos amida indazol como agentes serotoninergicos.
ES8704946A1 (es) Un procedimiento para la preparacion de triazolobenzodiazefinas.
PE26898A1 (es) Sales edulcorantes
MY132911A (en) Clear, injectable solution of an anesthetic compound
KR910004194A (ko) 안정한 주사용 수성 조성물 및 그러한 조성물의 안정화 방법
CZ293934B6 (cs) Injekční nebo infuzní roztoky enrofloxacinu a způsob jejich výroby
PA8534001A1 (es) Derivados de piperazina 1,4-disustituida utiles como bloqueadores alfa1,-adrenoceptores uro-selectivos
CO5021217A1 (es) Composiciones estables de mitoxantrona, procedimietno para prepararlas; utilizacion de dichas composiciones y medica- mentos que incluyen dichas soluciones para el tratamiento de enfermedades cancerosas
DK534087A (da) Desinfektionsmiddel indeholdende en stabiliseret hydrogenperoxidoploesning til desinfektion af bloede kontaktlinser
BG106414A (en) Bioavailable dosage form of isotretinoin
DE3573119D1 (en) 8-alkylthio-2-piperazino-pyrimidoû5,4-d¨pyrimidines, their preparation and medicaments containing them
ES2081783T1 (es) Alcaloides procedentes de mappia foetida, uso de estos y formulaciones que los contienen.
ES2101334T3 (es) Utilizacion terapeutica de la fosforil-l-serina-n-acil-esfingosina.
Koshita et al. Sulfhydryl oxidation induces calcium release from fragmented sarcoplasmic reticulum even in the presence of glutathione
DK0682522T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater indeholdende vecuroniumbromid

Legal Events

Date Code Title Description
FD Application declared void or lapsed